Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Predictive Immunohistochemical Biomarkers for Antibody-Drug Conjugate Therapy in Pulmonary Cytology. | Acta Cytol | 2026 | 42406652 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in colorectal cancer: current landscape and future perspectives from clinical trials. | Front Oncol | 2026 | 42404225 | PubTator, text mining | PubMed |
| Low-PSMA hormone-sensitive prostate cancer: a distinct clinical and molecular state. | Mol Med | 2026 | 42393527 | PubTator, text mining | PubMed |
| TROP2-targeted NIR-II Peptide Probe for Intraoperative Detection of Tumor Margins and Sentinel Nodes in Breast-conserving Surgery. | Radiol Imaging Cancer | 2026 | 42390488 | PubTator, text mining | PubMed |
| TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma. | Histopathology | 2026 | 42390022 | PubTator, text mining | PubMed |
| TROP2 targeting reveals therapy-driven cell state dynamics in colorectal cancer. | Nature | 2026 | 42386981 | PubTator, text mining | PubMed |
| [Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway®)]. | Nihon Yakurigaku Zasshi | 2026 | 42386645 | PubTator, text mining | PubMed |
| TROP2 antibody-drug conjugate: unique epitope engagement drives differentiated efficacy. | Antib Ther | 2026 | 42382977 | PubTator, text mining | PubMed |
| Cardiovascular Safety of Next-Generation Antibody-Drug Conjugates in HER2-Low and Triple-Negative Breast Cancer: A Narrative Review (2020-2025). | Cureus | 2026 | 42382890 | PubTator, text mining | PubMed |
| Engineering Cathepsin S Selective Chemical Probes and Antibody-Drug Conjugates through Substrate Profiling with Unnatural Amino Acids. | J Med Chem | 2026 | 42381118 | PubTator, text mining | PubMed |
| Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors. | Cancer Res Commun | 2026 | 42378456 | PubTator, text mining | PubMed |
| Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine. | Expert Rev Anticancer Ther | 2026 | 42376796 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in gynecologic malignancies: breakthroughs, challenges, and future directions. | Front Immunol | 2026 | 42375351 | PubTator, text mining | PubMed |
| TROP2 promotes bone metastasis of colorectal cancer through interaction with the fibronectin-integrin axis. | Cell Mol Life Sci | 2026 | 42371099 | PubTator, text mining | PubMed |
| Activity of datopotamab deruxtecan in TROP2-expressing low-grade serous ovarian cancer: a preclinical study. | Gynecol Oncol Rep | 2026 | 42368461 | PubTator, text mining | PubMed |
| Human epidermal growth factor receptor-2, nectin-4, and trophoblast cell surface antigen-2 expression varies significantly across ovarian cancer histotypes. | Taiwan J Obstet Gynecol | 2026 | 42362263 | PubTator, text mining | PubMed |
| A Comprehensive Bioinformatic Analysis of SLC52A3 as a Prognostic Biomarker and Potential Therapeutic Target in Gynecological Cancers. | Genes (Basel) | 2026 | 42353828 | PubTator, text mining | PubMed |
| A Cohort-Based Genetic Analysis of Keratoconus in Turkey Reveals a Substantial Proportion of Novel Variants and Suggests Possible Oligogenic Contributions to Keratoconus. | Genes (Basel) | 2026 | 42353764 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates in Solid Tumor Oncology and the Frontier of Precision Immunosuppression: A Mechanistic, Translational, and Clinical Review. | Int J Mol Sci | 2026 | 42352921 | PubTator, text mining | PubMed |
| Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer: A Systematic Review with Meta-Analysis of Single-Arm Efficacy and Integration of Randomized and Real-World Evidence. | Cancers (Basel) | 2026 | 42352537 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=6